Table 8 Reported incidence of hematological adverse events in clinical trials of TKIs in NSCLC
Drug | Trial Name | ORR (CR/PR) | mPFS (mo) | Neutropenia | Lymphopenia | Anemia | Thrombocytopenia | Reference | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
All grades (%) | Grade 3 and 4 (%) | All grades (%) | Grade 3 and 4 (%) | All grades (%) | Grade 3 and 4 (%) | All grades (%) | Grade 3 and 4 (%) | |||||
Osimertinib | FLAURA (NCT02296125) | 80% (3%/77%) | 18.9 | NA | 4/279 (1.4%) | NA | 4/279 (1.4%) | 34/279 (12.2%) | 3/279 (1.1%) | NA | 2/279 (0.7%) | |
Osimertinib | ADAURA (NCT02511106) | NA | NA | NA | 1/337 (0.3%) | NA | NA | NA | NA | NA | NA | Wu YL (2020) [46] |
Erlotinib and ramucirumab | RELAY (NCT02411448) | 76% (1%/75%) | 19.4 | 25/221 (11.3%) | 6/221 (2.7%) | NA | NA | 22/221 (10%) | 4/221 (1.8%) | 31/221 (14%) | 3/221 (1.4%) | Nakagawa K (2019) [56] |
Erlotinib | RELAY (NCT02411448) | 75% (1%/74%) | 12.4 | 16/225 (7.1%) | 2/225 (0.89%) | NA | NA | 10/225 (4.4%) | 1/225 (0.44%) | 6/225 (2.7%) | 0/225 (0%) | Nakagawa K (2019) [56] |
Gefitinib | ARCHER 1050 (NCT01774721) | 72% (2%/70%) | 9.2 | 4/224 (1.8%) | 1/224 (0.45%) | 2/224 (0.89%) | 1/224 (0.45%) | 16/224 (7.1%) | 5/224 (2.2%) | NA | NA | |
Afatinib | LUX-Lung 6 (NCT01121393) | 66.9% (1.2%/65.7%) | 11 | 2/239 (0.84%) | 1/239 (0.42%) | NA | NA | 19/239 (7.9%) | 1/239 (0.42%) | 4/239 (1.7%) | 0/239 (0%) | Wu YL (2014) [59] |
Dacomitinib | ARCHER 1050 (NCT01774721) | 75% (5%/70%) | 14.7 | 5/227 (2.2%) | 0/227 (0%) | 2/227 (0.88%) | 0/227 (0%) | 22/227 (9.7%) | 2/227 (0.88%) | NA | NA | |
Alectinib | J-ALEX (JapicCTI-132,316) | 92% (2%/89%) | NA | 3/103 (2.9%) | 2/103 (1.9%) | NA | NA | 6/103 (5.8%) | 1/103 (0.97%) | NA | NA | Hida T (2017) [60] |
Brigatinib | ALTA-1 L (NCT02737501) | 71% (4%/67%) | 12 | 2/136 (1.5%) | 0/136 (0%) | NA | NA | NA | NA | NA | NA | Camidge DR (2018) [61] |
Brigatinib | ALTA (NCT02094573) | Arm B: 54% | 12.9 | NA | NA | NA | NA | NA | NA | NA | NA | Kim D (2021) [62] |
Poziotinib | ZENITH20 (NCT03318939) | 27.8% | 5.5 | NA | NA | NA | NA | NA | NA | NA | NA | Ternyila D (2020) [63] |
Capmatinib | Geometry Mono-1 (NCT02414139) | 41% (0%/41%) | 5.4 | NA | NA | NA | NA | NA | NA | NA | NA | Wolf J (2020) [48] |
Selpercatinib | LIBRETTO-001 (NCT03157128) | 64% (2%/62%) | 16.5 | NA | NA | NA | NA | NA | NA | NA | NA | Drilon A (2020) [49] |